Halozyme Therapeutics, Inc. News, Halozyme Therapeutics, Inc. Quote, HALO Quote

Halozyme Therapeutics, Inc. (NQ:HALO) Delayed: 6.32 --0 (-0%)
Previous Close	$6.32	52 Week High	$9.92
Open	$6.41	52 Week Low	$3.86
Day High	$6.55	P/E	N/A
Day Low	$6.31	EPS	$-0.52
Volume	3,187

Friends, Peers and Foes (?): BAX, VPHM, ILMN, WFR, NKE (more...)

ALERTS | RSS

Jun 3, 2013 07:52 AM Halozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
May 24, 2013 04:58 PM Form 4 HALOZYME THERAPEUTICS For: May 22 Filed by: RAMSAY DAVID A
May 24, 2013 04:24 PM Form 8-K HALOZYME THERAPEUTICS For: May 20
May 23, 2013 08:03 AM Halozyme (HALO) Names David Ramsay as CFO
May 23, 2013 08:00 AM Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
May 21, 2013 09:00 AM Baxter Receives Marketing Authorization for HyQvia in European Union
May 20, 2013 12:08 PM Form 4 HALOZYME THERAPEUTICS For: May 16 Filed by: KIRK RANDAL J
May 17, 2013 05:27 PM Form 8-K HALOZYME THERAPEUTICS For: May 16
May 17, 2013 09:31 AM StreetInsider.com Pre-Open Movers 5/17: (HALO) (ORMP) (CLSN) Higher; (ARUN) (ADSK) (BRCD) Lower (more...)
May 16, 2013 07:41 PM Form 4 HALOZYME THERAPEUTICS For: May 16 Filed by: FALBERG KATHRYN E

Entities mentioned with HALO

View All Entities